Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28162815 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL29501895 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL29398319 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL28162814 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL29465008 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL197618 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL24733 | 1.00 | LMNA (0.52) | LMNAMAPK1FABP4FABP5CASP1 | |
| Hydrochloric Acid SCHEMBL1374028 | 0.98 | LMNA (0.50) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL28848826 | 0.98 | LMNA (0.50) | LMNAMAPK1FABP4FABP5CASP1 | |
| SCHEMBL28180751 | 0.98 | LMNA (0.50) | LMNAMAPK1FABP4FABP5CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115191-A1 | Nilotinib Compositions with Enhanced Solubility | NEOFORM BIOPHARMACEUTICAL LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20250340518-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | GLENMARK LIFE SCIENCES LTD (IN) | 2025-11-06 | — | — | US | claimed |
| EP-4536226-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | Alivus Life Sciences Limited (IN) | 2025-04-16 | — | — | EP | claimed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | claimed |
| US-20250069164-A1 | ENVIRONMENTAL ATTRIBUTES FOR CHEMICAL COMPOUNDS COMPRISING A CARBONYL GROUP | BASF SE (DE) | 2025-02-27 | — | — | US | claimed |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | METROCHEM API PVT LTD | 2025-01-02 | — | — | US | claimed |
| EP-4453829-A1 | ENVIRONMENTAL ATTRIBUTES FOR CHEMICAL COMPOUNDS COMPRISING A CARBONYL GROUP | BASF SE (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-114634492-B | Preparation method of lanoconazole | 浙江东亚药业股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| EP-3122708-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF EXAMETAZIME | JUBILANT GENERICS LTD (IN) | 2024-06-12 | — | — | EP | claimed |
| WO-2003000636-A1 | RESOLUTION PROCESS FOR (R)-(-)-2-HYDROXY-2-(2-CHLOROPHENYL) ACETIC ACID | SANOFI-SYNTHELABO (FR) | 2003-01-03 | — | — | WO | claimed |
| EP-1242589-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE ALPHA-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2002066410-A1 | PREPARATION OF MANDELIC ACID DERIVATIVES | AVECIA LIMITED (GB) | 2002-08-29 | — | — | WO | claimed |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | VERENIUM CORPORATION | 2002-01-31 | — | — | US | claimed |
| US-20010041359-A1 | Process for the preparation of optically and chemically highly pure (R) - or (S) -alpha- hydroxycarboxylic acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2001-11-15 | — | — | US | claimed |
| WO-2001048175-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE α-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| US-5614641-A | USING A PHOSPHINO-CONTAINING RUTHENIUM COMPLEX AS CATALYST | ELF AQUITAINE (FR) | 1997-03-25 | — | — | US | claimed |
| EP-0648201-B1 | ENANTIOSELECTIVE HYDROGENATION OF THE CARBONYL BOND USING RUTHENIUM COMPLEXES WITH BIPHOSPHINE LIGANDS | ELF AQUITAINE (FR) | 1997-01-22 | — | — | EP | claimed |
| EP-0648201-A1 | Enantioselective hydrogenation of the carbonyl bond using ruthenium complexes with biphosphine ligands. | ELF AQUITAINE (FR) | 1995-04-19 | — | — | EP | claimed |
| WO-1994001390-A1 | ENANTIOSELECTIVE CARBONYL GROUP HYDROGENATION METHOD USING RUTHENIUM/DIPHOSPHINE LIGAND COMPLEXES | ELF AQUITAINE (FR) | 1994-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | LMNA 2873/4885MAPK1 4077/4885FABP4 4440/4885 |
| US-20250340518-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | BRAF, KRAS, JAK2 | LMNA 2416/4885MAPK1 116/4885FABP4 3389/4885 |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, FLT3, BCR | LMNA 618/4885MAPK1 1811/4885FABP4 2186/4885 |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | RNGTT, ASPH, ALKBH3 | LMNA 1933/4885MAPK1 4046/4885FABP4 2410/4885 |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | TALDO1, AURKB, PGD | LMNA 1863/4885MAPK1 2164/4885FABP4 3122/4885 |
| US-20260115191-A1 | Nilotinib Compositions with Enhanced Solubility | TP53, PHF8, SMCHD1 | LMNA 3317/4885MAPK1 850/4885FABP4 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.